Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,690Revenue $M9.8Net Margin (%)-18,394.6Altman Z-Score5.4
Enterprise Value $M1,613EPS $-4.8Operating Margin %-18,458.0Piotroski F-Score1
P/E(ttm)--Beneish M-Score226Pre-tax Margin (%)-18,394.6Higher ROA y-yN
Price/Book12.710-y EBITDA Growth Rate %-4.9Quick Ratio3.2Cash flow > EarningsY
Price/Sales57,2135-y EBITDA Growth Rate %28.7Current Ratio3.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-78.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-97.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M45.3ROIC % (ttm)-451.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
$ 37.32122%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
$ 37.3266%Reduce 52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
$ 37.3218%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
$ 37.3247%Reduce 89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
$ 37.3226%Reduce 64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
$ 37.32-3%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
$ 37.3229%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
$ 37.3240%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
$ 37.32473%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
$ 37.32652%Reduce 83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
$ 37.32375%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
$ 37.32285%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.82197.12view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.82197.12view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95151.76view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.56179.62view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-5.18view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.970.43view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.687.47view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.112.93view
Price Ben GilDirector 2013-08-19Buy500$31.1812.64view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-8.78view

Quarterly/Annual Reports about SRPT:

    News about SRPT:

    Articles On GuruFocus.com
    Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
    Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
    Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
    Ebola: Is The Cure Out There? Oct 14 2014 
    Insiders Are Buying Fate Therapeutics Oct 09 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Feb 16 2013 

    More From Other Websites
    ​Here’s the latest on today’s FDA review of BioMarin’s Duchenne drug Nov 24 2015
    Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : November 24, 2015 Nov 24 2015
    ​The first drug for Duchenne will be reviewed at the FDA today: Why it matters Nov 24 2015
    IBB Leads Biotech ETFs with Rise of 3.1% Nov 23 2015
    BioMarin Down on FDA's Briefing Document on Kyndrisa Nov 23 2015
    Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : November 23,... Nov 23 2015
    KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers Nov 21 2015
    [$$] Biotech's Biggest Battle Nov 21 2015
    This Weekend's Barron's: Profiles of 16 Women Who Have Made the Top 100 Women Advisors for 10 Years... Nov 21 2015
    3 Stocks to Buy on Big Volume Nov 20 2015
    BioMarin's Pain is Sarepta's Gain, Right? Maybe Not. Nov 20 2015
    Duchenne moms say FDA documents ‘widen the divide’ between drugs by BioMarin, Sarepta Nov 20 2015
    This May be Biotech’s Next Huge Winner Nov 20 2015
    Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling Nov 20 2015
    4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming Nov 20 2015
    BioMarin Duchenne Drug Receives Harsh Review From FDA Nov 20 2015
    The biggest event in biotech this year Nov 19 2015
    These Biotech Stocks Could Move on BioMarin's Duchenne Drug FDA Panel Nov 19 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)